



SPAFID  
CONNECT

Informazione Regolamentata n. 20106-44-2021	Data/Ora Ricezione 13 Settembre 2021 13:12:56	MTA - Star
---	---	------------

Societa' : PHARMANUTRA  
Identificativo : 151777  
Informazione  
Regolamentata  
Nome utilizzatore : PHARMANUTRAN02 - Lacorte Roberto  
Tipologia : 1.2  
Data/Ora Ricezione : 13 Settembre 2021 13:12:56  
Data/Ora Inizio : 13 Settembre 2021 13:12:57  
Diffusione presunta  
Oggetto : PR - PHARMANUTRA - Half-Year  
Financial Report as of 30 June 2021

*Testo del comunicato*

Vedi allegato.

## PHARMANUTRA S.P.A.: HALF-YEAR FINANCIAL REPORT AS OF 30 JUNE 2021

Pisa, 13 September 2021 - PharmaNutra S.p.A. (MTA; Ticker PHN) announces that the Half – Year Financial Report as of 30th June 2021, as approved by the Board of Directors of the Company on September 6<sup>th</sup> 2021, as well the Auditors' Report, is available at the Company's registered office, on PharmaNutra S.p.A. website ([www.pharmanutra.it](http://www.pharmanutra.it), section *Investor Relations*) and on the authorized storage mechanism "eMarket Storage" available on the website ([www.emarketstorage.it](http://www.emarketstorage.it)).

### PharmaNutra S.p.A.

Established and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra is a company established in 2003 that develops unique nutritional supplements and innovative medical devices, taking care of the entire production process, from proprietary raw materials to the finished product. The effectiveness of the products is demonstrated by a number of scientific evidence, including more than 140 publications. The Group distributes and sells in Italy and abroad. In Italy, the sales activity is carried out through a network of over 150 Scientific Sales Representatives at the service of the medical class, also dedicated to the exclusive marketing of PharmaNutra products to pharmacies throughout the country. Sales abroad are guaranteed in over 50 countries through 39 partners selected among the leading pharmaceutical companies. PharmaNutra is a leader in the production of iron-based nutritional supplements under the brand name SiderAL<sup>®</sup>, for which it boasts key patents for the Sucrosomial<sup>®</sup> Technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, based on the integrated management of all components: proprietary raw materials, patents, trademarks and clinical evidence.

[PharmaNutra.it](http://PharmaNutra.it)

For further details:

### PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa, Italy  
Tel. +39 050 7846500  
[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

Internal Press Office  
[press@calabughi.com](mailto:press@calabughi.com)

### Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan, Italy  
Tel. +39 02 83635708

Matteo Russo  
[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)  
Cristina Tronconi  
[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

Fine Comunicato n.20106-44

Numero di Pagine: 3